BACKGROUND: We evaluated the impact of surgeon's volume on recurrence and progression in patients with newly diagnosed transitional cell carcinoma of the bladder after first transurethral resection (TUR) and second-TUR. METHODS: Between March 2005 and December 2012, 209 patients with intermediate-high risk primary bladder cancer who received second TUR within 2 to 6 weeks following the initial resection were prospectively included in a database and retrospectively analyzed. Surgeons were stratified into high-volume (>100 TUR) and low-volume (<100 TUR). Tumor recurrence and progression were analyzed respect to first and second-TUR and surgeon-volume. RESULTS: Of the 209 patients who underwent second-TUR, 57 (27.2%) had macroscopic tumors before resection, which correlated to tumors multiplicity. Stage and surgeon category were independent predictors of tumor recurrence, with a 5-year recurrence-free survival rate of 52.7% and 23.1% for high and low-volume surgeon, respectively (P<0.001). Stage and surgeon category at first and second-TUR were independent predictor of tumor progression, with a 5-year progression-free survival rate of 83.8% and 48.0% for high and low-volume surgeon, respectively (P<0.001). CONCLUSIONS: As for other major urological procedures, patients undergoing TUR performed by high volume surgeon may have better outcomes than patients operated by low-volume providers.
BACKGROUND: We evaluated the impact of surgeon's volume on recurrence and progression in patients with newly diagnosed transitional cell carcinoma of the bladder after first transurethral resection (TUR) and second-TUR. METHODS: Between March 2005 and December 2012, 209 patients with intermediate-high risk primary bladder cancer who received second TUR within 2 to 6 weeks following the initial resection were prospectively included in a database and retrospectively analyzed. Surgeons were stratified into high-volume (>100 TUR) and low-volume (<100 TUR). Tumor recurrence and progression were analyzed respect to first and second-TUR and surgeon-volume. RESULTS: Of the 209 patients who underwent second-TUR, 57 (27.2%) had macroscopic tumors before resection, which correlated to tumors multiplicity. Stage and surgeon category were independent predictors of tumor recurrence, with a 5-year recurrence-free survival rate of 52.7% and 23.1% for high and low-volume surgeon, respectively (P<0.001). Stage and surgeon category at first and second-TUR were independent predictor of tumor progression, with a 5-year progression-free survival rate of 83.8% and 48.0% for high and low-volume surgeon, respectively (P<0.001). CONCLUSIONS: As for other major urological procedures, patients undergoing TUR performed by high volume surgeon may have better outcomes than patients operated by low-volume providers.
Authors: Nicholas E Boxall; Fanourios Georgiades; Saiful Miah; Laurian Dragos; James Armitage; Tevita F Aho Journal: World J Urol Date: 2021-05-12 Impact factor: 4.226
Authors: Tae Hyuk Kim; Jee Soo Kim; Hyunju Park; Hye In Kim; Jun-Ho Choe; Man Ki Chung; Young Ik Son; Soo Yeon Hahn; Na-Young Hwang; Sook-Young Woo; Sun Wook Kim; Jae Hoon Chung Journal: Ann Surg Oncol Date: 2021-07-08 Impact factor: 5.344
Authors: Matteo Ferro; Giuseppe Di Lorenzo; Carlo Buonerba; Giuseppe Lucarelli; Giorgio Ivan Russo; Francesco Cantiello; Abdal Rahman Abu Farhan; Savino Di Stasi; Gennaro Musi; Rodolfo Hurle; Serretta Vincenzo; Gian Maria Busetto; Ettore De Berardinis; Sisto Perdonà; Marco Borghesi; Riccardo Schiavina; Gilberto L Almeida; Pierluigi Bove; Estevao Lima; Giovanni Grimaldi; Deliu Victor Matei; Francesco Alessandro Mistretta; Nicolae Crisan; Daniela Terracciano; Verze Paolo; Michele Battaglia; Giorgio Guazzoni; Riccardo Autorino; Giuseppe Morgia; Rocco Damiano; Matteo Muto; Roberto La Rocca; Vincenzo Mirone; Ottavio de Cobelli; Mihai Dorin Vartolomei Journal: J Cancer Date: 2018-10-20 Impact factor: 4.207